DrugPatentWatch Database Preview

Janssen R And D Company Profile

JANSSEN R AND D has two approved drugs.

There are four US patents protecting JANSSEN R AND D drugs.

There are one hundred and thirty-four patent family members on JANSSEN R AND D drugs in thirty-nine countries and twelve supplementary protection certificates in eleven countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-001	Jan 18, 2008		RX	Yes	No	8,003,789*PED	Start Trial			Y	Start Trial
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-001	Jan 18, 2008		RX	Yes	No	7,887,845*PED	Start Trial			Y	Start Trial
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-003	Mar 26, 2012		RX	Yes	No		Start Trial				Start Trial
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-001	Jan 18, 2008		RX	Yes	No	7,037,917*PED	Start Trial			Y	Start Trial
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-003	Mar 26, 2012		RX	Yes	No	7,037,917*PED	Start Trial			Y	Start Trial
Janssen R And D	PARAFON FORTE DSC	chlorzoxazone	TABLET;ORAL	011529-002	Jun 15, 1987		DISCN	Yes	No		Start Trial				Start Trial
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-003	Mar 26, 2012		RX	Yes	No	7,887,845*PED	Start Trial			Y	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-002	Dec 22, 2010	7,887,845*PED	Start Trial
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-003	Mar 26, 2012	7,887,845*PED	Start Trial
Janssen R And D	INTELENCE	etravirine	TABLET;ORAL	022187-001	Jan 18, 2008	7,887,845*PED	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	775360	Start Trial
World Intellectual Property Organization (WIPO)	0122938	Start Trial
Eurasian Patent Organization	200100534	Start Trial
Slovenia	1129079	Start Trial
Slovakia	285240	Start Trial
Spain	2258018	Start Trial
Indonesia	28545	Start Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1002795	337	Finland	Start Trial
1002795	C01002795/01	Switzerland	Start Trial	PRODUCT NAME: ETRAVIRIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58483 13.05.2008
1002795	SPC033/2008	Ireland	Start Trial	SPC033/2008: 20090914, EXPIRES: 20230827
1002795	SPC/GB09/003	United Kingdom	Start Trial	SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/003 GRANTED TO JANSSEN PHARMACEUTICA NV IN RESPECT OF THE PRODUCT ETRAVIRINE OPTIONALLY IN A FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6342 DATED 08 DECEMBER 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 AUGUST 2023.
1002795	CA 2009 00004	Denmark	Start Trial
1002795	300373	Netherlands	Start Trial	300373, 20191101, EXPIRES: 20230827
1002795	91528	Luxembourg	Start Trial	91528, EXPIRES: 20230828
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.